Login to Your Account



EMA Due to Report Final Rules for Biosimilar mABs this Year

By Nuala Moran
BioWorld International Correspondent

Wednesday, January 18, 2012
LONDON – The European Medicines Agency (EMA) is poised to take a significant step forward in the regulation of biosimilar drugs, with the publication of its final guideline on requirements for biosimilar monoclonal antibodies (mABs).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription